Collaboration pioneers cystic fibrosis treatment
A Bradford, UK company that is developing a gel technology that could revolutionise the way cystic fibrosis patients inhale drugs has been shortlisted for an award for its work with Bradford University.
A Bradford, UK company that is developing a gel technology that could revolutionise the way cystic fibrosis patients inhale drugs has been shortlisted for an award for its work with Bradford University.
The technology has the potential to improve the quality of life of millions of cystic fibrosis sufferers and significantly reduce the costs to the NHS for treating patients, the company says.
AGT Sciences has been shortlisted in the Strategic Partnership category in the annual Yorkshire Forward awards for its work with the University's Pharmaceutical Innovation Centre of Industrial Collaboration (CIC).
AGT Sciences develops wound care products and drug delivery systems using chemical technologies and has developed a hydrogel to solve a range of life science problems.
The company approached the CIC because it wanted to formulate a hydrogel system to successfully deliver drugs to the lung.
By working with the CIC, AGT Sciences proved that the concept worked and were able to achieve the suitable particle size and narrow distribution for delivery of drugs to the lung.
The advantage of hydrogel technology is that it can get further down into the lungs than existing drug delivery systems that should enable patients to take their drugs less frequently than they have to currently.